



In Vitro Anticancer Potentiality and Molecular Modelling Study of Novel Cyclic Pentapeptides based on 1, 2-benzenedicarbonyl chloride

Fatma H. Mohamed¹; Gaber O. Moustafa^{1*}, Eman S. Nossier², Marwa M. Mounier³

¹ Peptide Chemistry Department, Chemical Industries Research Division, National Research Centre, 12622-Dokki, Cairo, Egypt. fatmahassan1581993@gmail.com, gosman79@gmail.com

² Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt; dr.emannossier@gmail.com

³ Pharmacognosy Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Egypt, 33 EL Bohouth St., Dokki, Giza, P.O. Box 12622; marwa_m3@yahoo.com



CrossMark

In Loving Memory of Late Professor Doctor "Mohamed Refaat Hussein Mahran"

Abstract

Cancer continues to be a leading cause of significant mortality globally. The conventional treatment methods currently in use are accompanied by notable side effects, and their efficacy falls short of achieving curative outcomes. Moreover, the considerable costs, technical demands, and cytotoxicity contribute to their limitations. Given their comparatively higher priorities, bioactive peptides with anti-cancer properties have emerged as treatment options within the therapeutic repertoire. This paper describes the synthesis and evaluation of a set of Cyclo-(N α -phthaloyl)-bis-[dipeptide]-L- Lys -X, (X= ester, acid or hydrazide derivatives) with potential cytotoxic activity against four human cancer cell lines using MTT growth inhibition assay. Compound 8, in particular, demonstrated significant cytotoxicity against the human colon cancer cell line (CaCo-2). Furthermore, an additional exploration encompassed the molecular docking of the promising derivative 20 to examine its binding mode within the active site of the EGFR enzyme. The docking results indicate a favorable fit, attributed to various hydrogen bond interactions with protein residues, hinting at potential anticancer activity.

Keywords: Anti-cancer peptide, Bioactive peptide, cyclic pentapeptide, N α -phthaloyl-bis-peptides, cytotoxicity.

1. Introduction

Chemotherapy is one of the most important treatment modalities for liver cancer, especially for those who are judged as being unsuitable for surgical resection, local ablative therapy, or trans arterial chemoembolization. However, the efficacy of chemotherapy is still unsatisfactory due to the long duration, side effects and the tendency to develop drug resistance. The development of novel anti-cancer drugs remains imperative. Cyclopeptides have been recognized as new chemical modalities in drug design due to their unique constrained structures, extensive biological activities, higher metabolic stability, cell permeability and bioavailability than linear peptides. A lot of cyclic peptides have been found with potential anti-proliferative activity against malignant cells, and many of them showed excellent anti-cancer activity [1]. Numerous cyclic peptides employed in clinical settings predominantly stem from natural sources. The inherent features that render cyclic peptides appealing as lead compounds for drug development and valuable tools for

biochemical research have spurred diverse efforts by scientists to create biologically active cyclic peptide compounds [2]. Therapeutic cyclic peptides present a compelling alternative to proteins or antibodies, primarily due to their smaller size and exceptional ability to permeate cell membranes. These peptides showcase remarkable attributes, displaying high activity, specificity, and affinity while minimizing the potential for drug-drug interactions. Their versatility is evident in their diverse biological and chemical properties. An especially noteworthy advantage is their reduced accumulation in specific organs, a characteristic that contributes significantly to mitigating toxic side effects. This makes therapeutic cyclic peptides promising candidates for drug development, offering a balance between efficacy and safety in medical applications. [3]. Moreover, therapeutic peptide are easily modifiable [4] and exhibit lower immunogenicity compared to recombinant antibodies or proteins [5]. Peptides inherently interact with biological systems, making them potent therapeutics [6-8]. The development of anticancer agents has seen a rise in both natural and synthetic peptides [9,

*Corresponding author e-mail: gosman79@gmail.com

Receive Date: 26 December 2023, Revise Date: 30 January 2024, Accept Date: 12 February 2024

DOI: 10.21608/ejchem.2024.258520.9092

©2024 National Information and Documentation Center (NIDOC)

10], [11 -14]. The increasing number of peptides in clinical phases and advanced preclinical stages underscores their potential, making drug design and discovery in this domain a current research focus [15, [16 -21]. Peptide candidates exhibiting a spectrum of activities, including anticancer, anti-inflammatory, analgesic, and antimicrobial properties. [22 -49].

2. Experimental Details

2.1. Chemistry

IR Spectra were obtained using the Perkin Elmer FT-IR Spectrum BX apparatus. Melting points are uncorrected. Specific optical rotations were measured with a A. Krawss, Optronic, P8000 polarimeter. NMR Spectra were scanned in DMSO- d_6 on a Bruker NMR spectrophotometer at 400 MHz for ^1H NMR and 100 MHz for ^{13}C NMR. Mass spectra were obtained using a GCMS-QP1000 EX spectrometer (70 e.V.) Elemental analyses were performed at the Microanalytical Center of Cairo University. (R_f) was determined using Thin Layer Chromatography (TLC) eluted with silica gel aluminum sheets, 60 F254 (E. Merck), it was eluted with (S₁; Butanol/water/acetic acid/ pyridine; 120/48/12/40) or ethyl acetate).

2.1.1. Synthesis of phthaloyl dichloride, (2), was prepared according to the reported method [50].

2.1.2. General procedure for synthesis of (N^α -phthaloyl)-bis-[dipeptides], (3-12), was prepared according to the reported method [51].

2.1.3. General Procedure for Synthesis of cyclo-(N^α - Phthaloyl)-bis-[dipeptide]-L-Lys-OMe (Phthaloyl bridged cyclic Penta peptide methyl esters): (13-15).

ECF (2.9 ml, 30.1 mmol) was added to a stirred and cold solution (-20 °C) of Phthaloyl - bis - [dipeptide] (10-12), N^α - Phthaloyl - bis-[L-Ala - L-Phe - COOH], **10**, N^α - Phthaloyl - bis-[DL-NVa - DL-NVa -COOH], **11** and N^α - Phthaloyl - bis-[DL-NVa -L-Phe -COOH], **12**, (15.05 mmol) and TEA (3.3 ml, 30.1 mmol) in DCM (50 ml). The reaction mixture was stirred for additional 30 minutes, followed by the addition of an equivalent of free L-Lysine methyl ester (3.5 gm, 15.05 mmol, -20 °C) in DCM (50 ml). The reaction work up was continued according to the reported method [51] by the mixed anhydride method. The obtained solid was filtered off and precipitated from EtOH / pet. ether to afford the corresponding cyclic penta peptide methyl esters (**13-15**), Cyclo - (N^α - Phthaloyl)- bis-[L-Ala - L-Phe]- L-Lys -OMe, **13**, Cyclo - (N^α - Phthaloyl) - bis-[DL-

NVa - DL-NVa]- L - Lys -OMe, **14** and Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa -L-Phe]- L - Lys -OMe, **15**

Cyclo - (N^α - Phthaloyl) - bis-[L-Ala -L-Phe]-L-Lys-OMe, **13**

13. Yield: (90.9 %); m.p. 84–93 °C; [α] D = - 300 (C = 0.03).Rf x100 (the eluent) = 93.3 (S₁). IR (cm^{-1}): (KBr): ν = (KBr): ν = 3330 (NH stretching), 3070 (CH aromatic), 2945 (CH aliphatic), 1718 (C=O ester), 1648, 1536 and 1447 (C=O amide I, II and amide III, respectively). $^1\text{H-NMR}$ (500 MHz, ppm, DMSO- d_6): δ = 8.58-8.32 (s, 6H, 6NH, D₂O exchangeable), 7.90-7.15 (m, 14H, aromatic), 5.03, 5.02 (t, 2H, NHCHCH₂Phe, α CH), 4.15 (t, 1H, CH₂CHNH, α CH, Lys), 3.99 (q, 2H, 2CH, NHCHCH₃, L-Ala, α CH), 3.62 (s, 6H, 2COOCH₃), 3.40 (d, 4H, 2CH₂, CH₂Phe, β CH₂), 3.25 (t, 2H, NHCH₂CH₂, ϵ CH₂, Lys), 2.30-2.00 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ , δ , β CH₂, Lys), 1.60-1.11 (t, 6H, 2CH₃, NHCHCH₃, L-Ala, β CH₃). MS (EI, 70 eV): m/z (%) = **726.8 (M⁺, 0.10%)**, 727.8 (M⁺+1, 0.08%), 684.55 (0.16), 610 (2.01%), 541.70 (0.09%), 505.65 (0.59%), 403.75 (3.20%), 360.75 (8.39%), 277.80 (6.04%), 203.85 (4.88%), 130 (20.60 %), **90.95 (100%)**, 65 (10.03), 53 (1.31%). Molecular formula (M.wt.), C₃₉H₄₆N₆O₈(726.82); calculated analysis; C 64.45, H 6.38, N 11.56; found analysis; C 64.44, H 6.36, N 11.54.

Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - DL-NVa] - L - Lys -OMe; **14**

14. Yield: (89 %); m.p. 73-75 °C; Rf x100 (the eluent) = 67.2 (S₁). IR (cm^{-1}): (KBr): ν = (KBr): ν = 3309 (NH stretching), 3064 (CH aromatic), 2957 (CH aliphatic), 1730 (C=O ester), 1650, 1536 and 1452 (C=O amide I, II and amide III, respectively). $^1\text{H-NMR}$ (500 MHz, ppm, DMSO- d_6): δ = 9.00 (s, 6H, 6NH, D₂O exchangeable), 8.00-7.90 (m, 4H, aromatic), 4.65 (t, 4H, 4CH, NHCHCH₂, DL-NVa, α CH), 4.40 (t, 1H, CH₂CHNH, α CH, Lys), 3.85 (s, 3H, COOCH₃), 3.30 (m, 2H, NHCH₂CH₂, ϵ CH₂, Lys), 2.55 - 1.80 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ , δ , β CH₂, Lys), 1.50-1.35 (q, 8H, 4CH₂, DL-NVa, β CH₂), 1.20-1.10 (m, 2H, 2CH₂, DL-NVa, γ CH₂), 0.90-95 (s, 12H, 4CH₃, DL-NVa, δ CH₃). MS (EI, 70 eV): m/z (%) = **686.84 (M⁺, 0.22%)**, 687.8 (M⁺+1, 0.28%), 601 (0.23%), 562 (0.35), 504.65 (0.10%), 403.75 (0.19%), 377.75 (0.22%), 301.80 (24.37%), 217.90 (0.22%), 185.90 (2.04%), 104.90 (7.17%), **72 (100%)**, 53 (2.91%). Molecular formula (M.wt.), C₃₅H₅₄N₆O₈ (686.84); calculated analysis; C 61.20, H 7.92 N 12.24; found analysis; C 61.19, 7.91, N 12.22.

Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa -L-Phe]-L - Lys -OMe; **15**

15. Yield: (84.7 %); m.p. 96-98 °C; Rf x100 (the eluent) = 83.33 (S₁). IR (cm^{-1}): (KBr): ν = 3303 (NH

stretching), 3060 (CH, aromatic), 2949 (CH, aliphatic), 1717 (C=O, ester), 1647, 1536 and 1436 (C=O amide I, II and III, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ= 9.00 (s, 4H, 4NH, D₂O exchangeable), 8.10-7.90 (m, 14H, aromatic), 4.70-4.55 (t, 2H, NHCH₂CH₂Phe, α CH), 4.40 (t, 4H, 4CH, NHCH₂CH₂, DL-NVa, α CH), 4.00 (s, 3H, COOCH₃), 3.50 (m, 2H, NHCH₂CH₂, εCH₂, Lys), 3.25-3.15 (d, 4H, 2CH₂, CH₂Phe, β CH₂), 2.70 - 2.15 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 1.80-1.70 (q, 4H, 2CH₂, DL-NVa, β CH₂), 1.40 (m, 2H, 2CH₂, DL-NVa, γ CH₂), 0.90 (t, 6H, 2CH₃, DL-NVa, δ CH₃). MS (EI, 70 eV): m/z (%) = **782.92 (M⁺, 0.10%)**, 783.9 (M⁺+1, 0.04%), 720.6 (0.02%), 704.65 (0.05%), 655.70 (0.27%), 605.75 (1.07%), 514.75 (0.11%), 404.80 (1.30%), 300.85 (1.57%), 177.90 (0.20%), 120 (100%), 60.95 (0.29%), **55 (17.51%)**. Molecular formula (M.wt.), C₄₃H₅₄N₆O₈ (782.92): calculated analysis; C 65.97, H 6.95 N 10.73; found analysis; C 65.96, H 6.91, N 10.71.

2.1.4. General Procedure for Synthesis of cyclo-(N^α- Phthaloyl)-bis-[dipeptide] -L-Lys-COOH (Phthaloyl bridged cyclic Penta peptide carboxylic acid): (16-18).

To a stirred and cold methanolic solution (-5 °C, 20 ml) of cyclic penta peptide methyl esters (**13-15**), Cyclo - (N^α- Phthaloyl)- bis-[L-Ala - L-Phe]- L-Lys -OMe, **13**, Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa - DL-NVa]- L - Lys -OMe, **14** and Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa -L-Phe]- L - Lys -OMe, **15** (1 mmol), sodium hydroxide solution (1N, 25 ml) was (dropwisely) added. The reaction mixture work up was continued according to the reported method [51] to give the corresponding cyclic Penta peptide acids: (**16-18**), Cyclo - (N^α- Phthaloyl)- bis-[L-Ala - L-Phe]- L-Lys-COOH, **16**, Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa - DL-NVa]- L - Lys-COOH, **17** and Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa -L-Phe]- L - Lys-COOH, **18**.

Cyclo - (N^α- Phthaloyl) - bis-[L-Ala -L-Phe]-L-Lys-COOH, **16**

16. Yield: (88.5%); m.p. 187-189 °C; [α]_D = - 133 (C = 0.03). Rf x100 (the eluent) = 51.66 (S₁). IR (cm⁻¹): (KBr): ν = 3326 (NH stretching), 3064 (CH, aromatic), 2937 (CH, aliphatic), 1713 (C=O, acid), 1644 and 1538 (C=O amide I and II, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ= 12.85 (s, 1 H, OH, D₂O exchangeable), 8.55-8.09 (s, 6H, 6NH, D₂O exchangeable), 7.58-7.27 (m, 14H, aromatic), 4.96 (t, 2H, NHCH₂CH₂Phe, α CH), 4.31 (t, 1H, CH₂CHNH, α CH, Lys), 3.45 (q, 2H, 2CH, NHCH₂CH₂, L-Ala, α CH), 3.02 (d, 4H, 2CH₂, CH₂Phe, β CH₂), 3.00 (t, 2H, NHCH₂CH₂, εCH₂, Lys), 2.00 - 1.80 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 1.24, 1.17 (t, 6H, 2CH₃, NHCH₂CH₂, L-Ala, β CH₃). MS (EI, 70 eV):

m/z (%) = **740.80 (M⁺, 0.03%)**, 741.80 (M⁺+1, 0.02%), 641.55 (0.10), 600.7 (0.05%), 555.7 (0.05%), 503.75 (1.02%), 404.80 (2.41%), 300.9 (0.77%), 200.9 (0.99%), 155 (1.43%), 110.05 (2.53%), **91 (100%)**, 59 (5.61), 50 (10.30%). Molecular formula (M.wt.), C₃₉H₄₄N₆O₉ (740.80): calculated analysis; C 63.23, H 5.99, N 11.34; found analysis; C 63.20, H 5.96, N 11.32.

Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa - DL-NVa] - L - Lys-COOH; **17**

17. Yield: (89.7 %); m.p. 188-190 °C; Rf x100 (the eluent) = 77.85 (S₁). IR (cm⁻¹): (KBr): ν = 3413 (NH stretching), 3033 (CH, aromatic), 2960 (CH, aliphatic), 1709 (C=O, acid), 1642 and 1539 (C=O amide I and II, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ= 12.65 (s, 1 H, OH, D₂O exchangeable), 8.26 (s, 6H, 6NH, D₂O exchangeable), 7.66-7.53 (m, 4H, aromatic), 4.55 (t, 4H, 4CH, NHCH₂CH₂, DL-NVa, α CH), 4.31 (t, 1H, CH₂CHNH, α CH, Lys), 3.15 (m, 2H, NHCH₂CH₂, εCH₂, Lys), 2.40 - 1.95 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 1.65-1.45 (q, 8H, 4CH₂, DL-NVa, β CH₂), 1.35-1.25 (m, 2H, 2CH₂, DL-NVa, γ CH₂), 1.10-1.00 (s, 12H, 4CH₃, DL-NVa, δ CH₃). MS (EI, 70 eV): m/z (%) = **672.81 (M⁺, 0.03%)**, 673.8 (M⁺+1, 0.02%), 600 (0.04%), 550 (0.08%), 504 (0.05), 450.85 (0.27%), 403.90 (0.34%), 300.90 (8.94%), 265.95 (0.53%), 205.90 (0.48%), 157 (1.00%), **72.05 (100%)**, 59.05 (4.47%), 50 (11.86%). Molecular formula (M.wt.), C₃₄H₅₂N₆O₈ (672.81): calculated analysis; C 60.70, H 7.79, N 12.49; found analysis; C 60.68, H 7.77, N 12.47.

Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa -L-Phe]-L - Lys-COOH; **18**

18. Yield: (83.8 %); m.p. 112-114 °C; Rf x100 (the eluent) = 57.14 (S₁). IR (cm⁻¹): (KBr): ν = 3411 (NH stretching), 3063 (CH, aromatic), 2950 (CH, aliphatic), 1709 (C=O, acid), 1640 and 1541 (C=O amide I and II, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ= 12.55 (s, 1 H, OH, D₂O exchangeable), 8.80 (s, 4H, 4NH, D₂O exchangeable), 7.90-7.80 (m, 14H, aromatic), 4.96 (t, 2H, NHCH₂CH₂Phe, α CH), 4.50 (t, 4H, 4CH, NHCH₂CH₂, DL-NVa, α CH), 4.00 (m, 2H, NHCH₂CH₂, εCH₂, Lys), 3.12 (d, 4H, 2CH₂, CH₂Phe, β CH₂), 2.60 - 2.25 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 2.00 (q, 4H, 2CH₂, DL-NVa, β CH₂), 1.30 (m, 2H, 2CH₂, DL-NVa, γ CH₂), 0.90 (t, 6H, 2CH₃, DL-NVa, δ CH₃). MS (EI, 70 eV): m/z (%) = **768.90 (M⁺, 0.01%)**, 617.0 (0.03%), 550.85 (0.11%), 500.75 (0.09%), 460 (0.58%), 403 (1.14%), 322 (0.08%), 285 (1.05%), 214 (0.61%), 172 (1.52%), 110 (2.15%), **91 (100%)**, 60 (0.49%), 50 (4.52%). Molecular formula (M.wt.), C₄₂H₅₂N₆O₈ (768.90): calculated analysis; C 65.61, H 6.82, N 10.93; found analysis; C 65.59, H 6.80, N 10.90.

2.1.5. General Procedure for Synthesis of cyclo-(N^α- Phthaloyl)-bis-[dipeptide] -L-Lys-NHNH₂ (Phthaloyl bridged cyclic Penta peptide hydrazide): (19-21).

To a stirred methanolic solution (50 ml) of cyclic penta peptide methyl esters (13-15), (1 mmol), anhydrous hydrazine hydrate (0.35 ml, 10 mmol) was added. The reaction mixture work up was continued according to the reported method [51] to give the corresponding cyclic Penta peptide hydrazides: (19-21), Cyclo - (N^α- Phthaloyl)- bis-[L-Ala - L-Phe]-L- Lys-NHNH₂, **19**, Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa - DL-NVa]-L- Lys-NHNH₂, **20** and Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa -L-Phe]-L- Lys-NHNH₂, **21**.

Cyclo - (N^α- Phthaloyl) - bis-[L-Ala -L-Phe]-L- Lys-NHNH₂, **19**

19. Yield: (60 %); m.p. Decompose at 268-270 °C; [α]_D = -150 (C = 0.03). Rf x100 (the eluent) = 65 (S₁). IR (cm⁻¹): (KBr): ν = 3374 (NH stretching), 2924 (CH, aromatic), 2855 (CH, aliphatic), 1640, 1462 and 1320 (C=O amide I, II and III, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ = 9.85 (s, 1H, CONHNH₂), 8.07-7.82 (s, 6H, 6NH, D₂O exchangeable), 7.27-7.15 (m, 14H, aromatic), 4.96 (t, 2H, NHCHCH₂Phe, α CH), 4.55 (t, 2H, NHCHCH₂Phe, α CH), 4.30 (s, 2H, CONHNH₂), 4.20 (t, 1H, CH₂CHNH, α CH, Lys), 3.50 (q, 2H, 2CH, NHCHCH₃, L-Ala, α CH), 3.20 (d, 4H, 2CH₂, CH₂Phe, β CH₂), 3.05 (t, 2H, NHCH₂CH₂, εCH₂, Lys), 2.15-1.95 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 1.40, 1.20 (t, 6H, 2CH₃, NHCHCH₃, L-Ala, β CH₃). MS (EI, 70 eV): m/z (%) = **726.8 (M⁺, 0.03%), 728 (M⁺+1, 0.02 %), 664 (0.05%), 601 (0.98%), 559 (0.16%), 510 (0.11%), 452 (0.27%), 403 (0.86%), 308 (0.59%), 200 (2.13%), 161 (4.53%), 120 (100%), 85 (17.42%), 59 (12.37%)**. Molecular formula (M.wt.), C₃₈H₄₆N₈O₇ (726.82): calculated analysis; C 62.79, H 6.38, N 15.42; found analysis; C 62.78, H 6.36, N 15.40.

Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa - DL-NVa] - L- Lys-NHNH₂, **20**

19. Yield: (70 %); m.p. Decompose at 230-232 °C; Rf x100 (the eluent) = 75.4 (S₁). IR (cm⁻¹): (KBr): ν = 3272 (NH stretching), 3154 (CH, aromatic), 2940 (CH, aliphatic), 1647, 1573 and 1448 (C=O amide I, II and III, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ = 9.05 (s, 1H, CONHNH₂), 8.09-8.06 (s, 6H, 6NH, D₂O exchangeable), 7.88-7.85 (m, 4H, aromatic), 4.30 (t, 4H, 4CH, NHCHCH₂, DL-NVa, α CH), 4.25 (s, 2H, CONHNH₂), 4.15 (t, 1H, CH₂CHNH, α CH, Lys), 3.30 (m, 2H, NHCH₂CH₂, εCH₂, Lys), 2.10 - 1.85 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 1.40-1.20 (q, 8H, 4CH₂, DL-NVa, β CH₂), 1.15-1.00 (m, 2H, 2CH₂, DL-NVa, γ CH₂), 0.90-0.75 (s, 12H, 4CH₃, DL-NVa, δ CH₃). MS (EI, 70

eV): m/z (%) = **686.8 (M⁺, 0.03%), 687.8 (M⁺+ 1, 0.02%), 611 (0.06%), 549 (1.65%), 503 (0.41), 438 (0.58%), 379 (0.56%), 306 (0.48%), 205 (0.43%), 159 (17.62%), 110 (5.11%), 72 (100%), 59 (6.16%), 50 (3.43%)**. Molecular formula (M.wt.), C₃₄H₅₄N₈O₇ (686.84): calculated analysis; C 59.46, H 7.92, N 16.31; found analysis; C 59.44, H 7.90, N 16.30.

Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa -L-Phe]-L- Lys-NHNH₂, **21**.

21. Yield: (77.5 %); m.p. Decompose at 280-282 °C; Rf x100 (the eluent) = 84.9 (S₁). IR (cm⁻¹): (KBr): ν = 3410 (NH stretching), 2930 (CH, aromatic), 2887 (CH, aliphatic), 1618, 1469 and 1319 (C=O amide I, II and III, respectively). ¹H-NMR (500 MHz, ppm, DMSO-d₆): δ = 9.75 (s, 1H, CONHNH₂), 8.10-8.05 (s, 6H, 6NH, D₂O exchangeable), 7.86-7.19 (m, 14H, aromatic), 4.90 (t, 2H, NHCHCH₂Phe, α CH), 4.45 (t, 4H, 4CH, NHCHCH₂, DL-NVa, α CH), 4.25 (s, 2H, CONHNH₂), 4.10 (m, 2H, NHCH₂CH₂, εCH₂, Lys), 3.05 (d, 4H, 2CH₂, CH₂Phe, β CH₂), 2.75 - 2.40 (m, 6H, 3CH₂, NHCH₂CH₂CH₂CHNH, γ, δ, β CH₂, Lys), 2.00 (q, 4H, 2CH₂, DL-NVa, β CH₂), 1.45 (m, 2H, 2CH₂, DL-NVa, γ CH₂), 1.00-0.85 (t, 6H, 2CH₃, DL-NVa, δ CH₃). MS (EI, 70 eV): m/z (%) = **782.8 (M⁺, 0.02 %), 705 (0.06%), 633 (0.79%), 569 (0.09%), 501 (0.35%), 403 (1.33%), 334 (1.12%), 292 (1.92%), 228 (3.01%), 201 (20.51%), 159 (32.8%), 120 (88.9%), 72 (100%), 60 (3.91%), 50 (7.63)**. Molecular formula (M.wt.), C₄₂H₅₄N₈O₇ (782.93): calculated analysis; C 64.43, H 6.95, N 14.31; found analysis; C 64.41, H 6.92, N 14.28.

2.2. In-vitro cytotoxic activity against some selected human cancer cell lines

Human lung (A-549), colon (CaCo-2), prostate (PC-3) and breast (MCF) cancer cell were obtained from Karolinska Center, Department of Oncology and Pathology, Karolinska Institute and Hospital, Stockholm, Sweden. IC₅₀ values were performed using SPSS computer program (SPSS for windows, statistical analysis software package /version 9/ 1989 SPSS Inc., Chicago, USA). The procedure was done in laminar air flow cabinet bio safety class II level. Culturing and sub culturing were carried out according to Thabrew [52]. Doxorubicin was used as a positive control. DMSO used as negative control. Cell Viability Assay was done according to (Selim) [53] as described by Mosmann [54]. The cells were seeded at concentration of 10x10³ cells per well in case of MCF-7, 20x10³ cells/well in case of HCT-116 cell lines using 96-well plates at 37 °C. After 48 hours' incubation, the medium was aspirated and 40 μl MTT salt (2.5 mg/ml) were added and further incubated for 4 hours. 200 μl 10% sodium dodecyl sulphate (SDS) was added. The absorbance was measured at 595nm.

2.3. Molecular docking studies

The molecular modeling of Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - DL-NVa] - L- Lys-NHNH₂, **20** was carried out using Molecular Operating Environment (MOE, 10.2008) software. The X-ray crystallographic structure of EGFR co-crystallized with erlotinib as inhibitor (PDB ID: 1M17) [55] was downloaded from the protein data bank. The receptor was prepared for docking study using Protonate 3D protocol in MOE with default options followed by water molecules removal. The co-crystallized ligand was used to define the active site for docking. Docking setup was first validated by re-docking of the co-crystallized ligand in the vicinity of the active site of the receptor. The validated setup was then used in predicting the ligand-receptor interactions at the active site for compound **20**.

3. Results and Discussion

3.1. Chemistry

The coupling cyclization of the tetrapeptide precursors with L-Lysine-OMe to afford the cyclic pentapeptides could be considered as the critical synthetic step in this work. The synthesis cyclo-(N^α-phthaloyl)-bis-[dipeptide]-L-Lys-OMe (phthaloyl bridged cyclic pentapeptide methyl esters): (**13-15**) was based on phthaloyl-bis-[dipeptide] candidates, (**10-12**), which were converted to anhydride, formed with ethylchloroformate in the presence of TEA as tertiary base. The acid was then coupled with L-Lys-OMe in the presence of TEA. The IR spectra showed the presence of aromatic rings. The amide linkage confirmation was based on three characteristic bands observed at (1648, 1536, and 1447), (1650, 1536, and 1452), and (1647, 1536, and 1436) cm⁻¹, corresponding to the regions of amide I, II, and III, respectively. Additionally, the presence of the ester group was supported by the observation of bands at 1718, 1730, and 1717 cm⁻¹, respectively, ν (C=O) ester. In addition, the stretching vibration frequency of NH groups was observed at 3330, 3309 and 3303 cm⁻¹ respectively. The EIMS of the obtained products (**13-15**) revealed the presence of molecular ion peaks at m/z: 726, 686 and 782, with base peak at m/z: 90, 72 and 55 (100%) respectively, which are consistent with their molecular weights. The ¹H-NMR spectra confirmed the existence of a singlet (3H) at δ (3.61-4.00) ppm for the (CH₃ ester), a multiplet (4H) at δ (4.40-4.15) ppm for the (CHNH). Additionally, new characteristic signals appeared as a result of cyclization with L-Lysine ester: a multiplet (2H) at δ (3.32-3.5) ppm for the protons of the CH₂ adjacent to the NH group of lysine (NHCH₂), a multiplet (6H) at δ (1.80-2.70) ppm for the protons of the remaining CH₂ groups of lysine. The methyl groups of the L-Lys-OMe esters within the cyclic pentapeptides underwent conversion into carboxylic acid groups. The hydrolysis of pentapeptide methyl esters (**13-15**) with 1 N sodium hydroxide in methanol resulted in the formation of the corresponding

compounds: Cyclo - (N^α - Phthaloyl) - bis-[L-Ala - L-Phe]- L - Lys -COOH, **16**, Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - DL-NVa]- L - Lys -COOH, **17**, Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - L-Phe]- L - Lys -COOH, **18**. The IR spectra indicated the absence of the ν (C=O, ester) signal and, instead, revealed a band at 1713, 1709, and 1709 cm⁻¹, corresponding to the presence of the ν (C=O, acid). The EIMS of the obtained products (**16-18**) revealed the presence of molecular ion peaks at m/z: 740, 672 and 768, respectively, with base peak at m/z: 91, 72 and 91 (100%), respectively, which are consistent with their molecular weights. The ¹H-NMR spectra revealed the disappearance of the singlet (3H) for the (CH₃ ester) and the appearance of a singlet (1H) at δ (12.48-12.85) ppm for carboxylic (OH) protons, which are exchangeable with D₂O.


The methyl groups of the L-Lys-OMe of the cyclic pentapeptides were converted to hydrazide functions. Hydrazinolysis of pentapeptide methyl ester derivatives (**13-15**) with hydrazine hydrate in methanol afforded the corresponding: Cyclo - (N^α - Phthaloyl) - bis-[L-Ala - L-Phe]- L - Lys -NHNH₂, **19**, Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - DL-NVa]-L - Lys -NHNH₂, **20** and Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - L-Phe]- L - Lys -NHNH₂, **21**. The IR spectra indicated the absence of ν (C=O, ester), and the amide linkage was well identified by its three characteristic bands in (1640, 1462 and 1320), (1647, 1573 and 144) and (1618, 1469 and 1319) cm⁻¹ region respectively, (amide I, II and III respectively). In addition, the NH stretching vibrations of the amide and hydrazide groups appeared as a broad band centered at 3374, 3272 and 3410 cm⁻¹ respectively. The EIMS of the obtained products (**19-21**) revealed the presence of molecular ion peaks at m/z: 726, 686 and 782, respectively with base peak at m/z: 120, 72 and 72, respectively (100%), which are consistent with their molecular weights. The ¹H-NMR spectra revealed the disappearance of the singlet (3H) for the (CH₃ ester) and the appearance of a broad singlet (2H) at δ (4.25-4.30) ppm for the amino protons (NH₂). The amide (NH) protons appeared as singlets (7H) at δ (8.18-7.82) ppm which are exchangeable with D₂O (scheme 2) for compounds (**13-21**).

2.2 Anti cancer activity of compounds 13-21 against different human cancer cell lines using MTT assay.


The anticancer activity of all synthesized peptides (13-21) was assessed against four cancer cell lines—human lung (A 549), colon (CaCo-2), prostate (PC-3), and breast (MCF-7) cancer cells—utilizing the MTT growth inhibition assay at a concentration of 100 μM [54]. Positive and negative controls, Doxorubicin, and DMSO, respectively, were employed. The results are detailed in Table 1. As indicated in Table 1, Cyclo - (N^α- Phthaloyl) - bis-[DL-NVa - DL-NVa] - L - Lys -COOH, **17**,

displayed high cytotoxic activity against human lung (A 549), (growth inhibition 74.95%), while other compounds showed low cytotoxic activity. Cyclo - (N^α - Phthaloyl) - bis-[DL-NVa - DL-NVa] - L - Lys - NHNH₂, **20**, revealed moderate anti-cancer activity towards prostate (PC-3) cell line, however, it displayed high cytotoxic activity towards colon (CaCo-2) cell line (growth inhibition

61.12 and 70.02% respectively), whereas other compounds displayed from low to moderate cytotoxic activity against them. Regarding to colon (MCF-7) cell line, all compounds showed low to moderate cytotoxic activity towards it (growth inhibition from 4.12 to 55.05%).



Scheme 1. Pathways for synthesizing compounds (3-12)



Scheme 2. Pathways for synthesizing compounds (13-21)

Table1: The percentage of the cytotoxicity of the promising compounds towards human cancer cell lines at 100 μ M.

Compound NO	Compound Name	Growth Inhibition (%)			
		A-549	CaCo2	PC-3	MCF -7
13.	Cyclo - (N $^{\alpha}$ - Phthaloyl)- bis-[L-Ala – L-Phe]– L- Lys –OMe	2.71	38.35	19.77	45.65
14.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – DL-NVa]– L – Lys –OMe	22.48	26.2	14.35	4.13
15.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – L-Phe]– L – Lys –OMe	30.45	18.65	9.23	6.16
16.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[L-Ala – L-Phe]– L – Lys –COOH	8.55	66.4	48.35	55.05
17.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – DL-NVa]– L – Lys –COOH	74.95	29.5	13.6	52.5
18.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – L-Phe]– L – Lys –COOH	8.21	46.05	31.6	29.15
19.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[L-Ala – L-Phe]– L – Lys - NHHN $_2$	5.75	20.33	16.85	23.65
20.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – DL-NVa]– L – Lys - NHHN $_2$	8.6	70.02	61.12	48.74
21.	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – L-Phe]– L – Lys - NHHN $_2$	32.005	37.4	22.15	54.1
DMSO		0	0	0	0
Doxorubicin		100	100	100	100

IC $_{50}$ was determined for compounds which achieved higher cytotoxic activity (> 70%). Doxorubicin served as the reference drug in this analysis, as presented in Table 2.

Table 2; IC $_{50}$ of compound 20 which has the highest cytotoxic activity (> 70%) against CaCo -2 cell line.

Compd No.		IC50 (Mean \pm SD) (mM) a
		CaCo -2 cell line
20	Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – DL-NVa]– L – Lys - NHHN $_2$	87.9 \pm 1.3
Doxorubicin		0.065 \pm 1.00

The IC $_{50}$ values, along with their standard errors (\pm), were calculated using the SPSS statistical program.

3.2. Molecular docking studies

Depending on the promising cytotoxic activities of the newly synthesized Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – DL-NVa] – L – Lys - NHHN $_2$, **20**, the docking study was applied using Molecular Operating Environment (MOE $^{\text{®}}$) 2008.10 [56]. To illustrate their mechanism of action. Upon continuation of our research on isophthalamide based derivatives that revealed anticancer activities targeting the epidermal growth factor receptor (EGFR) [57], the docking study of Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-[DL-NVa – DL-NVa] – L – Lys - NHHN $_2$, **20**, was achieved against EGFR to evaluate the binding affinity and the possible interactions. The X-ray crystallographic structure of EGFR bound with its ligand erlotinib was downloaded from protein data bank (pdb Id: 1M17) [57]. Redocking of the original ligand was established to evaluate RMSD value (1.02 Å°).

The original inhibitor (erlotinib) shared the binding with a hydrogen bond acceptor between its quinazoline nitrogen atom and the backbone of Met769 (distance: 2.70 Å) [56]. Figure 1.

The docking of the phthaloyl bridged cyclic pentapeptide hydrazide; Cyclo - (N $^{\alpha}$ - Phthaloyl) - bis-

[DL-NVa – DL-NVa] – L – Lys - NHHN $_2$, **20** was inserted in figure 2. The benzamide part played an essential role in binding via formation of two arene-cation interactions with Lys730 and Lys851 and fixation of Glu734 within the centre of the cyclic shape via hydrogen bonding with NH group. On the other hand, the terminal amino group formed H-bond donor and acceptor with the backbone of Asp831 and Gly833 (distance: 2.54 and 2.57 Å , respectively).

4. Conclusion

The primary objective of this study was to synthesize novel cyclic pentapeptides using phthaloyl dichloride (1, 2-benzenedicarbonyl chloride). The synthesized compounds, characterized by diverse spectral data, conform to the general structures of Cyclo-(N $^{\alpha}$ -phthaloyl)-bis-[dipeptide]-L-Lys-X, where X represents ester, acid, or hydrazide. The cytotoxic activities of these novel peptide candidates were evaluated against four human carcinoma cell lines (CaCo-2, A-549, MCF-7, and PC-3) using MTT assay at a concentration of 100 μ M. Several compounds exhibited significant cytotoxic activity, particularly against CaCo-2 cell lines. Molecular docking studies were conducted for the highly

promising derivative 20 within the EGFR binding site to elucidate its mechanism of action. The conclusion suggests the necessity for further comprehensive biological investigations, particularly conventional anticancer studies using experimental animal models.




Figure 1. (A & B) the 2D and 3D visualization docking of erlotinib into the binding site of EGFR, PDB: 1M17. Hydrogen bonds are illustrated as dotted lines with arrows, while carbon (C) atoms are shaded in gray, nitrogen (N) in blue, and oxygen (O) in red.





Figure 2: (A & B) the 2D and 3D visualization docking of compound 20 into the binding site of EGFR, PDB: 1M17. green color signifies the hydrophobic area, pink indicates the high polar area, and blue designates the mild polar area. Hydrogen bonds are depicted as dotted lines with arrows, with carbon (C) atoms colored gray, nitrogen (N) in blue, and oxygen (O) in red.

5. References

1. Kumar, S., Tiwari, A., Tiwari, V., Khokra, S. L., Saharan, R., Kumar, M., Sharma, A., Virmani, T., Virmani, R., Kumar, G., Alhalmi, A. Synthesis, Anticancer, and Antimicrobial Evaluation of Integerrimide-A. *BioMed Research International*, 2023, 2023, 9289141.
2. Joo, S.H. Cyclic peptides as therapeutic agents and biochemical tools. *Biomolecules & therapeutics*, 2012, 20(1), 19.
3. Marqus, S.; Pirogova, E.; Piva, T.J. Evaluation of the Use of Therapeutic Peptides for Cancer Treatment. *J. Biomed. Sci.* **2017**, *24*, 1–15.
4. J Boohaker, R.; W Lee, M.; Vishnubhotla, P.; LM Perez, J.; R Khaled, A. The Use of Therapeutic Peptides to Target and to Kill Cancer Cells. *Curr. Med. Chem.* **2012**, *19*, 3794–3804.
5. McGregor, D.P. Discovering and Improving Novel Peptide Therapeutics. *Curr. Opin. Pharmacol.* **2008**, *8*, 616–619.
6. Fjell, C.D.; Hiss, J.A.; Hancock, R.E.; Schneider, G. Designing Antimicrobial Peptides: Form Follows Function. *Nat. Rev. Drug Discov.* **2012**, *11*, 37–51.
7. Castanho, M.; Santos, N. *Peptide Drug Discovery and Development: Translational Research in Academia and Industry*; John Wiley & Sons, 2011; ISBN 3-527-63674-9.
8. Gademann, K.; Kimmmerlin, T.; Hoyer, D.; Seebach, D. Peptide Folding Induces High and Selective Affinity of a Linear and Small β -Peptide to the Human Somatostatin Receptor 4. *J. Med. Chem.* **2001**, *44*, 2460–2468.
9. Cicero, A.F.; Fogacci, F.; Colletti, A. Potential Role of Bioactive Peptides in Prevention and Treatment of Chronic Diseases: A Narrative Review. *Br. J. Pharmacol.* **2017**, *174*, 1378–1394.
10. Blanco-Míguez, A.; Gutiérrez-Jácome, A.; Pérez-Pérez, M.; Pérez-Rodríguez, G.; Catalán-García, S.; Fdez-Riverola, F.; Lourenço, A.; Sánchez, B. From Amino Acid Sequence to Bioactivity: The Biomedical Potential of Antitumor Peptides. *Protein*

- Sci.* **2016**, *25*, 1084–1095.
11. Xu, H.-M.; Yi, H.; Zhou, W.-B.; He, W.-J.; Zeng, G.-Z.; Xu, W.-Y.; Tan, N.-H. Tataricins A and B, Two Novel Cyclotetrapeptides from Aster Tataricus, and Their Absolute Configuration Assignment. *Tetrahedron Lett.* **2013**, *54*, 1380–1383.
 12. Sewald, N.; Jakubke, H. Peptide and Protein Design, Pseudopeptides, and Peptidomimetics. *Pept. Chem. Biol. Wiley-VCH Verl. GmbH Co KGaA* **2002**, 339–78.
 13. Lau, J.L.; Dunn, M.K. Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. *Bioorg. Med. Chem.* **2018**, *26*, 2700–2707.
 14. ABO-GHALIA, M.; FLEGEL, M.; BLANOT, D.; VAN HEIJENOORT, J. Synthesis of Inhibitors of the Meso-diaminopimelate-adding Enzyme from Escherichia Coli. *Int. J. Pept. Protein Res.* **1988**, *32*, 208–222.
 15. Albericio, F.; Kruger, H.G. Therapeutic Peptides. *Future Med. Chem.* **2012**, *4*, 1527–1531.
 16. Ali, L.; Rizvi, T.S.; Shaheen, F. *Syntheses of Anticancer Cyclic Peptides, Phakellistatin 12 & 13: A Comparative Study of Various Linkers and Cyclization Strategies Employed in Solid-Phase Peptide Synthesis*; LAP LAMBERT Academic Publishing, 2012; ISBN 3-8443-8589-4.
 17. Acharya, M.R.; Sparreboom, A.; Venitz, J.; Figg, W.D. Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. *Mol. Pharmacol.* **2005**, *68*, 917–932.
 18. Pratap, J.; Akech, J.; Wixted, J.J.; Szabo, G.; Hussain, S.; McGee-Lawrence, M.E.; Li, X.; Bedard, K.; Dhillon, R.J.; Van Wijnen, A.J. The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss. *Mol. Cancer Ther.* **2010**, *9*, 3210–3220.
 19. Feliu, L.; Oliveras, G.; Cirac, A.D.; Besalú, E.; Rosés, C.; Colomer, R.; Bardají, E.; Planas, M.; Puig, T. Antimicrobial Cyclic Decapeptides with Anticancer Activity. *Peptides* **2010**, *31*, 2017–2026.
 20. Shakeel, E.; Arora, D.; Jamal, Q.; Akhtar, S.; Khan, M.; Ahmad, K.; Kamal, M.A.; Siddiqui, M.; Lohani, M.; Arif, J.M. Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management. *Curr. Drug Metab.* **2018**, *19*, 523–543.
 21. Felício, M.R.; Silva, O.N.; Gonçalves, S.; Santos, N.C.; Franco, O.L. Peptides with Dual Antimicrobial and Anticancer Activities. *Front. Chem.* **2017**, *5*, 5.
 22. Abo-Ghalia, M.H.; Moustafa, G.O.; Alwasidi, A.S.; Naglah, A.M. Cytotoxic Investigation of Isophthaloyl Cyclopenta peptides. *Lat. Am. J. Pharm.* **2017**, *36*, 1957-1962.
 23. Moustafa, G.O.; El-Sawy, A.A.; Abo-Ghalia, M.H. Synthesis of novel cyclopeptide candidates: I-cyclo-[N^α-isophthaloyl-bis-(Glycine-amino acid)-L-lysine] derivatives with expected anticancer activity. *Egypt. J. Chem.* **2013**, *5*, 473–494.
 24. Hassan, A.S.; Moustafa, G.O.; Awad, H.M. Synthesis and *in vitro* anticancer activity of pyrazolo [1, 5-a] pyrimidines and pyrazolo [3, 4-d][1, 2, 3] triazines. *Synth. Commun.* **2017**, *47*, 21, 1963-1972.
 25. Moustafa, G.O.; Younis, A.; Al-Yousef, S.A.; Mahmoud, S.Y. Design, synthesis of novel cyclic pentapeptide derivatives based on 1, 2-benzenedicarbonyl chloride with expected anticancer activity. *J. Comput. Theor. Nanosci.* **2019**, *16*, 5–6, 1733–1739.
 26. Mohamed, F.H.; Shalaby, A.M.; Soliman, H.A.; Abdelazem, A.Z.; Mounier, M.M.; Nossier, E.S.; Moustafa, G.O. Design, Synthesis and Molecular Docking Studies of Novel Cyclic Pentapeptides Based on Phthaloyl Chloride with Expected Anticancer Activity. *Egypt. J. Chem.* **2020**, *63*, 5, 1723-1736, DOI: 10.21608/EJCHEM.2019.18452.2137
 27. Abo-Ghalia, M.H.; Moustafa, G.O.; Amr, A.E.; Naglah, A.M.; Elsayed, E.A.; Bakheit, A.H. Anticancer activities and 3D-QSAR studies of some new synthesized macrocyclic heptapeptide derivatives. *Molecules.* **2020**, *25*(5), 1253.
 28. Kalmouch, A.; Radwan, M.A.A.; Omran, M.M.; Sharaky, M.; Moustafa, G.O. Synthesis of novel 2, 3'-bipyrrrole derivatives from chalcone and amino acids as antitumor agents. *Egypt. J. Chem.* **2020**, *63*, 11, 4409 – 4421
 29. Moustafa, G.O., Al-Wasidi, A.S., Naglah, A.M., Refat, M.S. Isolation and Synthesis of Dibenzofuran Derivatives Possessing Anticancer Activities: A Review. *Egyptian Journal of Chemistry*, **2020**, *63* (6), 2355-2367.
 30. Elhenawy, A.A.; Al-Harbi, L.M.; Moustafa, G.O.; El-Gazzar, M.A.; Abdel-Rahman, R.F.; Salim, A.E. Synthesis, comparative docking, and pharmacological activity of naproxen amino acid derivatives as possible anti-inflammatory and analgesic agents. *Drug Des. Devel. Ther.* **2019**, *13*, 1773.
 31. Moustafa, G.O.; Khalaf, H.; Naglah, A.; Al-Wasidi, A.; Al-Jafshar, N.; Awad, H. Synthesis, Molecular Docking Studies, *In Vitro* Antimicrobial and Antifungal Activities of Novel Dipeptide Derivatives Based on N-(2-(2-hydrazinyl-2-oxoethylamino)-2-oxoethyl)-Nicotinamide. *Molecules.* **2018**, *23*, 761, DOI: 10.3390/molecules23040761
 32. Naglah, A.M.; Moustafa, G.O.; Al-Omar, M.A.; Al-Salem, H.A.S.; Hozzein, W.N. Synthesis, Characterization and *In Vitro* Antimicrobial Investigation of Novel Amino Acids and Dipeptides Based on Dibenzofuran-2-Sulfonyl-Chloride. *J. Comput. Theor. Nanosci.* **2017**, *14*, 3183-3190.
 33. Al-Salem, H.A.S.; Naglah, A.M.; Moustafa, G.O.; Mahmoud, A.Z.; Al-Omar, M.A. Synthesis of Novel Tripeptides Based on Dibenzofuran-2-Sulfonyl-[Aromatic and Hydroxy Aromatic Residues]: Towards Antimicrobial and Antifungal Agents. *J. Comput. Theor. Nanosci.* **2017**, *14*, 3958–3966.
 34. Hassan, A.S.; Moustafa, G.O.; Askar, A.A.; Naglah, A.M.; Al-Omar, M.A. Synthesis and antibacterial evaluation of fused pyrazoles and Schiff bases. *Synth. Commun.* **2018**, *48*, 21, 2761-2772.
 35. Hassan, A.S.; Askar, A.A.; Nossier, E.S.; Naglah, A.M.; Moustafa, G.O.; Al-Omar, M.A. Antibacterial Evaluation, *In Silico* Characters and Molecular Docking of Schiff Bases Derived from 5-aminopyrazoles. *Molecules.* **2019**, *24*, 17, 3130.
 36. Hasanin, M.S.; Moustafa, G.O. New potential green, bioactive and antimicrobial nanocomposites based on cellulose and amino acid. *International Journal of Biological Macromolecules.* **2019**,

- 144, 441-448. DOI: 10.1016/j.ijbiomac.2019.12.133.
37. Elsherif, M.A.; Hassan, A.S.; Moustafa, G.O.; Awad, H.M.; Morsy, N.M., Antimicrobial Evaluation and Molecular Properties Prediction of Pyrazolines Incorporating Benzofuran and Pyrazole Moieties. *J Appl Pharm Sci*, **2020**, *10* (02), 037-043.
 38. Hassan, A.S.; Moustafa, G.O.; Morsy, N.M.; Abdou, A.M.; Hafez, T.S. Design, synthesis and antibacterial activity of N-aryl-3-(arylamino)-5-(((5-substituted furan-2-yl)methylene)amino)-1H-pyrazole-4-carboxamide as Nitrofurantoin® analogues. *Egypt. J. Chem.* **2020**, *63*, 11, 4485 - 4497.
 39. Khalaf, H.S., Naglah, A.M., Al-Omar, M.A., Moustafa, G.O.; Awad, H.M., Bakheit, A.H. Synthesis, docking, computational studies, and antimicrobial evaluations of new dipeptide derivatives based on nicotinoylglycylglycine hydrazide. *Molecules*, **2020**, *25* (16), 3589.
 40. Al-Wasidi, A.S., Naglah, A.M., Kalmouch, A., Adam, A.M.A., Refat, M.S., Moustafa, G.O. Preparation of Cr₂O₃, MnO₂, Fe₂O₃, NiO, CuO, and ZnO oxides using their glycine complexes as precursors for in situ thermal decomposition. *Egyptian Journal of Chemistry*, **2020**, *63* (3), 1109-1118.
 41. Al-Wasidi, A.S., Naglah, A.M., Refat, M.S., El-Megharbel, S.M., Kalmouch, A., Moustafa, G.O. Synthesis, spectroscopic characterization and antimicrobial studies of Mn(II), Co(II), Ni(II), Cr(III) and Fe(III) melatonin drug complexes. *Egyptian Journal of Chemistry*, **2020**, *63* (4), 1469-1481.
 42. Al-Wasidi, A.S., Wafeek, M. Abd El-Ghaffar, H.A., Naglah, A.M., Kalmouch, A., Hamed, M., Moustafa, G.O. Effect of Density on Growth Hormone and Some Physiological Parameters and its Relation to Growth Performance. *Egyptian Journal of Chemistry*, **2020**, *63* (4), 1575-1584
 43. Naglah, A.M., Moustafa, G.O., Elhenawy, A.A., Mounier, M.M., El-Sayed, H., Al-Omar, M.A. Almehezia, A.A., Bhat, M.A. N^α-1, 3-Benzenedicarbonyl-bis-(Amino Acid) and Dipeptide Candidates: Synthesis, Cytotoxic, Antimicrobial, Antifungal and Molecular Docking Investigation. *Drug Design, Development and Therapy*, **2021**, *15*, 1315-1332.
 44. Moustafa, G.O., Therapeutic Potentials of Cyclic Peptides as Promising Anticancer Drugs. *Egyptian Journal of Chemistry*, **2021**, *64* (4), 1777-1787.
 45. Moustafa, G.O., Synthesis of dibenzofuran derivatives possessing anti-bacterial activities, *Egyptian Journal of Chemistry*, **2021**, *64* (4), 2075-2093.
 46. Moustafa, G.O., Synthesis of Dibenzofurans Possessing Anti-Allergy, Antioxidant, Anti-Inflammatory, Antimalarial and Treatment of Skin Conditions, *Egyptian Journal of Chemistry*, **2021**, *64*(5), 2539-2556
 47. Hassan, A. S., Moustafa, G. O., Awad, H. M., Nossier, E. S., & Mady, M. F. (2021). Design, Synthesis, Anticancer Evaluation, Enzymatic Assays, and a Molecular Modeling Study of Novel Pyrazole-Indole Hybrids. *ACS Omega*, **2021**, *6*, 12361-12374.
 48. Eman A. Abd El-Meguid, Gaber O. Moustafa, Hanem M. Awad, Eman R. Zaki, Eman S. Nossier, Novel benzothiazole hybrids targeting EGFR: Design, synthesis, biological evaluation and molecular docking studies, *journal of molecular structure*, **2021**, *1240*, 130595
 49. Abd El-Meguid, E. A., Naglah, A. M., Moustafa, G. O., Awad, H. M. and El Kerdawy, A. M. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. *Bioorganic & Medicinal Chemistry Letters*, **2022**, *58*, 128529.
 50. Tang, X.; Cheng, X.T.; Huang, F.L. Synthesis of Ortho Phthaloyl Chloride Using Triphosgene by Response Surface Methodology.; Trans Tech Publ, 2013; Vol. 634, pp. 3026–3032.
 51. Mohamed, F.H.; Shalaby, A.; Abdelazem, A.; Mounier, M.; Nossier, E.; Moustafa, G. Design, Synthesis and Molecular Docking Studies of Novel Cyclic Pentapeptides Based on Phthaloyl Chloride with Expected Anticancer Activity. *Egypt. J. Chem.* **2020**, *63*, 25–26.
 52. Thabrew, M.I.; HUGHES, R.D.; MCFARLANE, I.G. Screening of Hepatoprotective Plant Components Using a HepG2 Cell Cytotoxicity Assay. *J. Pharm. Pharmacol.* **1997**, *49*, 1132–1135.
 53. Selim, M.S.; Amer, S.K.; Mohamed, S.S.; Mounier, M.M.; Rifaat, H.M. Production and Characterisation of Exopolysaccharide from Streptomyces Carpaticus Isolated from Marine Sediments in Egypt and Its Effect on Breast and Colon Cell Lines. *J. Genet. Eng. Biotechnol.* **2018**, *16*, 23–28.
 54. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. *J. Immunol. Methods* **1983**, *65*, 55–63.
 55. Amr, A.E.-G.E.; Abo-Ghalia, M.H.; Moustafa, G.O.; Al-Omar, M.A.; Nossier, E.S.; Elsayed, E.A. Design, Synthesis and Docking Studies of Novel Macrocyclic Pentapeptides as Anticancer Multi-Targeted Kinase Inhibitors. *Molecules* **2018**, *23*, 2416.
 56. Nossier, E.S.; El-Karim, A.; Somaia, S.; Khalifa, N.M.; El-Sayed, A.S.; Hassan, E.S.; El-Hallouty, S.M. Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives. *Molecules* **2018**, *23*, 3074.
 57. Kassem, A.F.; Moustafa, G.O.; Nossier, E.S.; Khalaf, H.S.; Mounier, M.M.; Al-Yousef, S.A.; Mahmoud, S.Y. In Vitro Anticancer Potentiality and Molecular Modelling Study of Novel Amino Acid Derivatives Based on N 1, N 3-Bis-(1-Hydrazinyl-1-Oxopropan-2-Yl) Isophthalamide. *J. Enzyme Inhib. Med. Chem.* **2019**, *34*, 1247–1258.